1. Home
  2. ADBT vs SER Comparison

ADBT vs SER Comparison

Compare ADBT & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Advasa Holdings Inc. Common Stock

ADBT

Advasa Holdings Inc. Common Stock

N/A

Current Price

$0.11

Market Cap

55.0M

Sector

Technology

ML Signal

N/A

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

N/A

Current Price

$1.81

Market Cap

56.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADBT
SER
Founded
2017
2017
Country
Japan
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.0M
56.4M
IPO Year
2025
2024

Fundamental Metrics

Financial Performance
Metric
ADBT
SER
Price
$0.11
$1.81
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $9.50
AVG Volume (30 Days)
★ 7.8M
40.0K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.01
N/A
Revenue
N/A
★ $130,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.15
★ N/A
Revenue Growth
N/A
★ 132.14
52 Week Low
$0.09
$1.22
52 Week High
$4.99
$4.99

Technical Indicators

Market Signals
Indicator
ADBT
SER
Relative Strength Index (RSI) 5.95 57.05
Support Level $0.10 $1.81
Resistance Level $0.13 $2.13
Average True Range (ATR) 0.01 0.28
MACD 0.09 0.04
Stochastic Oscillator 12.12 61.02

Price Performance

Historical Comparison
ADBT
SER

About ADBT Advasa Holdings Inc. Common Stock

Advasa Holdings Inc is a financial technology and services company that offers a suite of financial services and solutions. Its earned wage access (EWA) service, named 'FUKUPE', provides employees with real-time access to their earned wages through cashless receipts and settlements that integrate seamlessly with wallets, cards, and bank accounts. The company also licenses its EWA technology portfolio and offers OEM (original equipment manufacturer) services. The company generates the majority of revenue from the provision of software maintenance services. Geographically, the company operates only in Japan.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Share on Social Networks: